Proteon Therapeutics, Inc. (PRTO) financial statements (2021 and earlier)

Company profile

Business Address 1 LITTLE WEST 12TH STREET
NEW YORK, NY 10014
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:62242416584
Cash and cash equivalents61921364069
Short-term investments  2152515
Other undisclosed cash, cash equivalents, and short-term investments03(0)(0)00
Restricted cash and investments0     
Prepaid expense     1
Other undisclosed current assets11111(0)
Total current assets:72343436785
Noncurrent Assets
Property, plant and equipment 00000
Restricted cash and investments 0    
Other noncurrent assets  0010
Total noncurrent assets: 00110
TOTAL ASSETS:72444446885
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities139543
Accounts payable000111
Accrued liabilities039531
Employee-related liabilities     1
Other liabilities    1 
Other undisclosed current liabilities     (1)
Total current liabilities:139542
Noncurrent Liabilities
Total liabilities:139542
Stockholders' equity
Stockholders' equity attributable to parent, including:62035386382
Common stock 00000
Additional paid in capital213209203198195192
Accumulated other comprehensive income (loss)00(0) (0)(0)
Accumulated deficit(225)(210)(190)(160)(131)(110)
Other undisclosed stockholders' equity attributable to parent182222   
Total stockholders' equity:62035386382
TOTAL LIABILITIES AND EQUITY:72444446885

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:     3
Operating expenses(15)(21)(30)(29)(21)(11)
Operating loss:(15)(21)(30)(29)(21)(8)
Nonoperating income (expense)0100(1)4
Investment income, nonoperating000000
Other nonoperating income (expense) 00(0)(1)5
Interest and debt expense     (1)
Loss from continuing operations before income taxes:(15)(21)(30)(29)(21)(4)
Income tax benefit     0
Net loss:(15)(21)(30)(29)(21)(4)
Other undisclosed net income attributable to parent     1
Net loss attributable to parent:(15)(21)(30)(29)(21)(3)
Preferred stock dividends and other adjustments  (7)  (6)
Net loss available to common stockholders, diluted:(15)(21)(37)(29)(21)(10)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(15)(21)(30)(29)(21)(4)
Other comprehensive loss     (3)
Comprehensive loss:(15)(21)(30)(29)(21)(7)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)0(0)0(0) 
Comprehensive loss, net of tax, attributable to parent:(15)(21)(30)(29)(21)(7)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: